News >

Time-Limited Therapy With Drug Cessation Feasible in CLL

Kristi Rosa
Published: Friday, Jan 04, 2019

John F. Seymour, MBBS, PhD
John F. Seymour, MBBS, PhD
Targeted agents are here to stay when it comes to chronic lymphocytic leukemia (CLL), said John F. Seymour, MBBS, PhD. Additionally, combination therapies, as demonstrated by the phase III MURANO trial, can achieve deeper responses and enable the use of time-limited therapy in this patient population.

“The difficulty with all of the novel agents [being used as] single agents, is that they need to be given continuously until progression; that's because the complete remission rate, and particularly, the undetectable MRD (uMRD) remission rate as single agents for all of [these options] are relatively low,” said Seymour. “If we're to achieve time-limited therapy, we need to achieve undetectable MRD to allow treatment to be stopped.”

MURANO was the first phase III randomized trial to evaluate the combination of venetoclax (Venclexta) and rituximab (Rituxan) compared with bendamustine plus rituximab (BR) in 389 patients with relapsed/refractory CLL. Patients were administered venetoclax for 2 years and rituximab for the first 6 months, or 6 cycles of bendamustine plus rituximab for the duration of 6 months.

Results of the primary analysis showed that time-limited treatment with venetoclax and rituximab was associated with an 84% reduction in the hazard for disease progression or death at 3 years versus rituximab and bendamustine.1 Based on these data, the European Commission approved the combination in November 2018 for the treatment of patients with relapsed/refractory CLL following at least 1 prior therapy.

The FDA had granted an accelerated approval to venetoclax for patients with CLL or small lymphocytic lymphoma (SLL) harboring a 17p deletion [del(17p)], following at least 1 prior therapy in 2016. This transitioned into a full approval in June 2018 for patients with CLL/SLL, with or without del(17p), following at least 1 prior therapy. Simultaneously, it was approved for use in combination with rituximab in the same patient population.

In an analysis presented at the 2018 ASH Annual Meeting, investigators evaluated the benefit of venetoclax and rituximab in patients on study at a median follow-up of 36 months.2 Results showed that continued substantial PFS and OS benefits were observed with venetoclax treatment. Additionally, the rate of CLL progression after 1 year of completing venetoclax was 13%, supporting the feasibility and safety of a time-limited duration of the combination treatment.

“The combination of venetoclax and rituximab is able to achieve uMRD,” said Seymour.

In an interview with OncLive, Seymour discussed the clinical implications of the MURANO trial and highlighted the feasibility for time-limited therapy and its benefits for patients with CLL.

OncLive: How was the MURANO trial designed?

Seymour: MURANO [was a trial with] a superiority design. It was randomized [trial that tested the venetoclax combination] head-to-head in a 1:1 fashion against BR. Initially, there was no crossover built into the study, so patients who progressed on either arm then received treatment at physician’s discretion.

The trial has now been modified such that there is a crossover. Patients progressing on BR will receive venetoclax/rituximab, and those patients progressing after withdrawal of venetoclax will be retreated with venetoclax/rituximab. That amendment will give us more detail about subsequent therapy, and particularly, response to retreatment with venetoclax-based therapy.

What were the results presented at the 2018 ASH Annual Meeting?

The results of the MURANO study at initial analysis had been published in the New England Journal [of Medicine] in 2018. The superiority [data]—in terms of PFS and higher rates of uMRD—for the venetoclax combination have already been established and published.

The main emphasis of the presentation [at the 2018 ASH Annual Meeting] was the outcome of patients in the venetoclax/rituximab arm after drug cessation. We now have nearly 12 months of median follow-up data. In all patients, regardless of MRD status, who stopped venetoclax at the 2-year period, the likelihood of PFS 1 year later is 87%. This shows that as a general treatment strategy, time-limited therapy with drug cessation is feasible and safe.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication